Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.92
NYSE:PFE's Cash to Debt is ranked higher than
59% of the 773 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.62 vs. NYSE:PFE: 0.92 )
NYSE:PFE' s 10-Year Cash to Debt Range
Min: 0.14   Max: 3.47
Current: 0.92

0.14
3.47
Equity to Asset 0.45
NYSE:PFE's Equity to Asset is ranked higher than
54% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.61 vs. NYSE:PFE: 0.45 )
NYSE:PFE' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.66
Current: 0.45

0.37
0.66
Interest Coverage 11.11
NYSE:PFE's Interest Coverage is ranked higher than
55% of the 433 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 124.75 vs. NYSE:PFE: 11.11 )
NYSE:PFE' s 10-Year Interest Coverage Range
Min: 5.27   Max: 46.18
Current: 11.11

5.27
46.18
F-Score: 5
Z-Score: 2.56
M-Score: -2.97
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 30.47
NYSE:PFE's Operating margin (%) is ranked higher than
96% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.93 vs. NYSE:PFE: 30.47 )
NYSE:PFE' s 10-Year Operating margin (%) Range
Min: 9.51   Max: 35.89
Current: 30.47

9.51
35.89
Net-margin (%) 42.65
NYSE:PFE's Net-margin (%) is ranked higher than
98% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.07 vs. NYSE:PFE: 42.65 )
NYSE:PFE' s 10-Year Net-margin (%) Range
Min: 8.74   Max: 42.65
Current: 42.65

8.74
42.65
ROE (%) 28.83
NYSE:PFE's ROE (%) is ranked higher than
98% of the 727 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. NYSE:PFE: 28.83 )
NYSE:PFE' s 10-Year ROE (%) Range
Min: 5.98   Max: 52.59
Current: 28.83

5.98
52.59
ROA (%) 12.78
NYSE:PFE's ROA (%) is ranked higher than
96% of the 748 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.87 vs. NYSE:PFE: 12.78 )
NYSE:PFE' s 10-Year ROA (%) Range
Min: 3.35   Max: 25.31
Current: 12.78

3.35
25.31
ROC (Joel Greenblatt) (%) 83.18
NYSE:PFE's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.91 vs. NYSE:PFE: 83.18 )
NYSE:PFE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 19.53   Max: 88.78
Current: 83.18

19.53
88.78
Revenue Growth (%) -2.50
NYSE:PFE's Revenue Growth (%) is ranked higher than
56% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. NYSE:PFE: -2.50 )
NYSE:PFE' s 10-Year Revenue Growth (%) Range
Min: -2.5   Max: 19.1
Current: -2.5

-2.5
19.1
EBITDA Growth (%) 11.80
NYSE:PFE's EBITDA Growth (%) is ranked higher than
77% of the 594 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.60 vs. NYSE:PFE: 11.80 )
NYSE:PFE' s 10-Year EBITDA Growth (%) Range
Min: -4.7   Max: 35.5
Current: 11.8

-4.7
35.5
EPS Growth (%) 17.00
NYSE:PFE's EPS Growth (%) is ranked higher than
81% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. NYSE:PFE: 17.00 )
NYSE:PFE' s 10-Year EPS Growth (%) Range
Min: -26.8   Max: 90.5
Current: 17

-26.8
90.5
» NYSE:PFE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

PFE Guru Trades in Q3 2013

Louis Moore Bacon 17,687 sh (New)
Ray Dalio 54,608 sh (New)
Paul Tudor Jones 950,000 sh (+380.53%)
Joel Greenblatt 65,050 sh (+259.55%)
Jean-Marie Eveillard 8,276,410 sh (+174.32%)
John Buckingham 60,187 sh (+73.94%)
Mario Gabelli 1,202,843 sh (+14.31%)
Diamond Hill Capital 7,992,003 sh (+0.51%)
Manning & Napier Advisors, Inc 1,119,010 sh (+0.15%)
David Dreman 71,195 sh (+0.14%)
James Barrow 60,897,666 sh (+0.11%)
Robert Bruce 432,000 sh (unchged)
Michael Price 347,100 sh (unchged)
Donald Yacktman 41,700 sh (unchged)
Prem Watsa 235,000 sh (unchged)
Jeff Auxier 166,874 sh (unchged)
Brian Rogers 12,287,115 sh (unchged)
Ruane Cunniff 10,422 sh (unchged)
Mark Hillman 23,982 sh (unchged)
Ken Fisher 30,714,170 sh (-0.08%)
Murray Stahl 58,665 sh (-0.37%)
John Keeley 106,620 sh (-0.51%)
RS Investment Management 2,105,755 sh (-0.96%)
Dodge & Cox 67,406,435 sh (-1.15%)
Irving Kahn 2,508,002 sh (-1.32%)
Bill Frels 2,584,820 sh (-1.34%)
HOTCHKIS & WILEY 202,100 sh (-1.41%)
Charles Brandes 6,360,407 sh (-1.72%)
Ronald Muhlenkamp 34,944 sh (-3.9%)
Pioneer Investments 9,473,843 sh (-5.05%)
Vanguard Health Care Fund 21,393,422 sh (-10.74%)
NWQ Managers 11,116,160 sh (-12.7%)
Jeremy Grantham 47,726,111 sh (-17.75%)
Steven Cohen 113,826 sh (-93.25%)
» More
Q4 2013

PFE Guru Trades in Q4 2013

Jim Simons 7,499,841 sh (New)
Joel Greenblatt 222,280 sh (+241.71%)
Ray Dalio 110,408 sh (+102.18%)
Ronald Muhlenkamp 45,129 sh (+29.15%)
Jean-Marie Eveillard 10,186,005 sh (+23.07%)
Ruane Cunniff 11,022 sh (+5.76%)
Murray Stahl 61,605 sh (+5.01%)
John Buckingham 63,034 sh (+4.73%)
Robert Bruce 452,000 sh (+4.63%)
Diamond Hill Capital 8,339,063 sh (+4.34%)
James Barrow 61,461,287 sh (+0.93%)
Michael Price 347,100 sh (unchged)
Brian Rogers 12,287,115 sh (unchged)
Prem Watsa 235,000 sh (unchged)
Mark Hillman 23,982 sh (unchged)
Donald Yacktman Sold Out
Louis Moore Bacon Sold Out
Ken Fisher 30,626,382 sh (-0.29%)
Bill Frels 2,570,105 sh (-0.57%)
RS Investment Management 2,072,255 sh (-1.59%)
Mario Gabelli 1,183,743 sh (-1.59%)
John Keeley 104,466 sh (-2.02%)
Dodge & Cox 65,289,814 sh (-3.14%)
HOTCHKIS & WILEY 194,900 sh (-3.56%)
NWQ Managers 10,684,522 sh (-3.88%)
Jeff Auxier 159,324 sh (-4.52%)
Pioneer Investments 9,027,655 sh (-4.71%)
Manning & Napier Advisors, Inc 1,027,334 sh (-8.19%)
Steven Cohen 103,596 sh (-8.99%)
Charles Brandes 5,767,402 sh (-9.32%)
Irving Kahn 1,899,759 sh (-24.25%)
Vanguard Health Care Fund 12,153,122 sh (-43.19%)
Jeremy Grantham 26,803,828 sh (-43.84%)
David Dreman 10,163 sh (-85.73%)
Paul Tudor Jones 46,247 sh (-95.13%)
» More
Q1 2014

PFE Guru Trades in Q1 2014

Caxton Associates 100,000 sh (New)
Louis Moore Bacon 200,452 sh (New)
John Hussman 17,000 sh (New)
Paul Tudor Jones 875,000 sh (+1792.01%)
Joel Greenblatt 1,014,808 sh (+356.54%)
Steven Cohen 295,765 sh (+185.5%)
David Dreman 11,851 sh (+16.61%)
Irving Kahn 2,112,819 sh (+11.22%)
Diamond Hill Capital 8,790,937 sh (+5.42%)
John Buckingham 65,971 sh (+4.66%)
Murray Stahl 62,855 sh (+2.03%)
Ray Dalio 112,108 sh (+1.54%)
RS Investment Management 2,080,155 sh (+0.38%)
Brian Rogers 12,287,115 sh (unchged)
Ruane Cunniff 11,022 sh (unchged)
Michael Price 347,100 sh (unchged)
Robert Bruce 452,000 sh (unchged)
Louis Moore Bacon 600,000 sh (unchged)
Prem Watsa 235,000 sh (unchged)
Bill Frels 2,561,304 sh (-0.34%)
HOTCHKIS & WILEY 194,200 sh (-0.36%)
Charles Brandes 5,743,711 sh (-0.41%)
Ken Fisher 30,242,537 sh (-1.25%)
Mario Gabelli 1,165,574 sh (-1.53%)
Dodge & Cox 64,121,017 sh (-1.79%)
James Barrow 59,895,571 sh (-2.55%)
Pioneer Investments 8,653,390 sh (-4.15%)
John Keeley 95,893 sh (-8.21%)
Jeff Auxier 145,881 sh (-8.44%)
Ronald Muhlenkamp 41,169 sh (-8.77%)
Manning & Napier Advisors, Inc 899,181 sh (-12.47%)
NWQ Managers 9,231,207 sh (-13.6%)
Jean-Marie Eveillard 7,866,473 sh (-22.77%)
Vanguard Health Care Fund 7,276,622 sh (-40.13%)
Jeremy Grantham 6,741,800 sh (-74.85%)
Jim Simons 454,241 sh (-93.94%)
» More
Q2 2014

PFE Guru Trades in Q2 2014

Vanguard Health Care Fund 14,934,022 sh (+105.23%)
Ken Fisher 31,482,489 sh (+4.1%)
Brian Rogers 12,287,115 sh (unchged)
Manning & Napier Advisors, Inc 882,317 sh (-1.88%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:PFE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2014-06-30 Add 105.23%0.62%$29.02 - $32.4 $ 29.26-3%14934022
Vanguard Health Care Fund 2014-03-31 Reduce -40.13%0.48%$29.66 - $32.75 $ 29.26-7%7276622
Joel Greenblatt 2014-03-31 Add 356.54%0.38%$29.66 - $32.75 $ 29.26-7%1014808
Jean-Marie Eveillard 2014-03-31 Reduce -22.77%0.19%$29.66 - $32.75 $ 29.26-7%7866473
John Hussman 2014-03-31 New Buy0.04%$29.66 - $32.75 $ 29.26-7%17000
Vanguard Health Care Fund 2013-12-31 Reduce -43.19%0.91%$28.24 - $32.2 $ 29.26-5%12153122
Charles Brandes 2013-12-31 Reduce -9.32%0.22%$28.24 - $32.2 $ 29.26-5%5767402
Jean-Marie Eveillard 2013-12-31 Add 23.07%0.16%$28.24 - $32.2 $ 29.26-5%10186005
David Dreman 2013-12-31 Reduce -85.73%0.15%$28.24 - $32.2 $ 29.26-5%10163
Joel Greenblatt 2013-12-31 Add 241.71%0.11%$28.24 - $32.2 $ 29.26-5%222280
Ronald Muhlenkamp 2013-12-31 Add 29.15%0.05%$28.24 - $32.2 $ 29.26-5%45129
Donald Yacktman 2013-12-31 Sold Out 0.01%$28.24 - $32.2 $ 29.26-5%0
Ray Dalio 2013-12-31 Add 102.18%0.01%$28.24 - $32.2 $ 29.26-5%110408
Jean-Marie Eveillard 2013-09-30 Add 174.32%0.44%$27.65 - $29.67 $ 29.262%8276410
Vanguard Health Care Fund 2013-09-30 Reduce -10.74%0.27%$27.65 - $29.67 $ 29.262%21393422
Joel Greenblatt 2013-09-30 Add 259.55%0.04%$27.65 - $29.67 $ 29.262%65050
Ray Dalio 2013-09-30 New Buy0.01%$27.65 - $29.67 $ 29.262%54608
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 9.50
NYSE:PFE's P/E(ttm) is ranked higher than
97% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 41.40 vs. NYSE:PFE: 9.50 )
NYSE:PFE' s 10-Year P/E(ttm) Range
Min: 7.67   Max: 200.11
Current: 9.5

7.67
200.11
P/B 2.40
NYSE:PFE's P/B is ranked higher than
75% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.22 vs. NYSE:PFE: 2.40 )
NYSE:PFE' s 10-Year P/B Range
Min: 1.32   Max: 4.55
Current: 2.4

1.32
4.55
P/S 3.90
NYSE:PFE's P/S is ranked higher than
66% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.55 vs. NYSE:PFE: 3.90 )
NYSE:PFE' s 10-Year P/S Range
Min: 1.72   Max: 6.36
Current: 3.9

1.72
6.36
PFCF 11.70
NYSE:PFE's PFCF is ranked higher than
96% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. NYSE:PFE: 11.70 )
NYSE:PFE' s 10-Year PFCF Range
Min: 5.02   Max: 35.16
Current: 11.7

5.02
35.16
EV-to-EBIT 13.78
NYSE:PFE's EV-to-EBIT is ranked higher than
89% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.81 vs. NYSE:PFE: 13.78 )
NYSE:PFE' s 10-Year EV-to-EBIT Range
Min: 7.9   Max: 69.7
Current: 13.78

7.9
69.7
PEG 2.20
NYSE:PFE's PEG is ranked higher than
86% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 367.50 vs. NYSE:PFE: 2.20 )
NYSE:PFE' s 10-Year PEG Range
Min: 1.14   Max: 584
Current: 2.2

1.14
584
Shiller P/E 17.20
NYSE:PFE's Shiller P/E is ranked higher than
92% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. NYSE:PFE: 17.20 )
NYSE:PFE' s 10-Year Shiller P/E Range
Min: 8.49   Max: 40.05
Current: 17.2

8.49
40.05
Current Ratio 2.33
NYSE:PFE's Current Ratio is ranked higher than
70% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. NYSE:PFE: 2.33 )
NYSE:PFE' s 10-Year Current Ratio Range
Min: 0.98   Max: 3.18
Current: 2.33

0.98
3.18
Quick Ratio 2.09
NYSE:PFE's Quick Ratio is ranked higher than
74% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. NYSE:PFE: 2.09 )
NYSE:PFE' s 10-Year Quick Ratio Range
Min: 0.74   Max: 2.86
Current: 2.09

0.74
2.86

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.40
NYSE:PFE's Dividend Yield is ranked higher than
89% of the 453 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. NYSE:PFE: 3.40 )
NYSE:PFE' s 10-Year Dividend Yield Range
Min: 1.54   Max: 10.4
Current: 3.4

1.54
10.4
Dividend Payout 0.66
NYSE:PFE's Dividend Payout is ranked higher than
86% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. NYSE:PFE: 0.66 )
NYSE:PFE' s 10-Year Dividend Payout Range
Min: 0.12   Max: 8.21
Current: 0.66

0.12
8.21
Dividend growth (3y) 10.10
NYSE:PFE's Dividend growth (3y) is ranked higher than
84% of the 317 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.50 vs. NYSE:PFE: 10.10 )
NYSE:PFE' s 10-Year Dividend growth (3y) Range
Min: -14.7   Max: 22.6
Current: 10.1

-14.7
22.6
Yield on cost (5-Year) 4.51
NYSE:PFE's Yield on cost (5-Year) is ranked higher than
90% of the 461 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.39 vs. NYSE:PFE: 4.51 )
NYSE:PFE' s 10-Year Yield on cost (5-Year) Range
Min: 2.04   Max: 13.79
Current: 4.51

2.04
13.79
Share Buyback Rate 5.10
NYSE:PFE's Share Buyback Rate is ranked higher than
92% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.70 vs. NYSE:PFE: 5.10 )
NYSE:PFE' s 10-Year Share Buyback Rate Range
Min: 5.1   Max: -19
Current: 5.1

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 0.90
NYSE:PFE's Price/DCF (Projected) is ranked higher than
97% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. NYSE:PFE: 0.90 )
NYSE:PFE' s 10-Year Price/DCF (Projected) Range
Min: 0.53   Max: 8.57
Current: 0.9

0.53
8.57
Price/Median PS Value 1.10
NYSE:PFE's Price/Median PS Value is ranked higher than
72% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. NYSE:PFE: 1.10 )
NYSE:PFE' s 10-Year Price/Median PS Value Range
Min: 0.51   Max: 3.64
Current: 1.1

0.51
3.64
Price/Peter Lynch Fair Value 2.10
NYSE:PFE's Price/Peter Lynch Fair Value is ranked higher than
90% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. NYSE:PFE: 2.10 )
NYSE:PFE' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.17   Max: 36.51
Current: 2.1

1.17
36.51
Earnings Yield (Greenblatt) 7.30
NYSE:PFE's Earnings Yield (Greenblatt) is ranked higher than
81% of the 624 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. NYSE:PFE: 7.30 )
NYSE:PFE' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 12.6
Current: 7.3

1.4
12.6
Forward Rate of Return (Yacktman) 14.20
NYSE:PFE's Forward Rate of Return (Yacktman) is ranked higher than
85% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. NYSE:PFE: 14.20 )
NYSE:PFE' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 7.6   Max: 20.7
Current: 14.2

7.6
20.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, RHHBY, NVS, ABT » details
Traded in other countries:PFZ.UK, PFEBC.Belgium, PFE.Sweden, PFE.Switzerland, PFE.Germany
Pfizer was founded in 1849 and is a global pharmaceutical firm which develops and produces medicines and vaccines for a range of conditions which include ares of immunology, inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain. Pfizer's businesses include five prescription-only biopharmaceutical businesses and Pfizer Consumer Healthcare. Primary care, Specialty Care and Oncology are responsible for life-cycle management of in-line products and new proof of concept therapies. Pfizer's Board of Directors is responsible for the oversight of management, including the overall strategic direction of the company and for the company's policies on governance, executive compensation, transparency and compliance.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

SEENSCO
ReplySEENSCO - 1 month ago
PFE is trading at the low end of our short-term valuation range ($29-$36) and significantly below our Fair Value estimate of $42.41.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide